20
Feb
2024
2024
Kisolite’s Regulatory Pathway
by Kisolite Corp.
February 20th, 2024
in Corporate & Milestones
Kisolite Corp receives feedback from FDA Center for Drug Evaluation and Research (CDER) stating that Kisolite API should be an over-the-counter (OTC) drug.